

2025

5.28 (wed.) 12:10
12:50

12:10-12:15

◆ Introduction

12:15-12:40

◆ Seminar
(Presentation)

12:40-12:50

◆ Q&A

Online
(Zoom)Scan here for
Registration ▶▶https://us02web.zoom.us/webinar/register/WN_oQBmDhZTSWKh9k45ZJztow

Supported by Kyushu University, Q-AOS

Allergic diseases as modern diseases and our proposed formulations for their treatment



Key Words

Allergy

Professor

Takeshi MORI

Faculty of Engineering Department of Applied Chemistry

Takeshi Mori was born in Nagasaki Prefecture, Japan in 1974 and received PhD in 2001 from Kyushu University. Immediately thereafter he joined Tokushima University, where he worked as an assistant professor for 4 years then moved to Kyushu University in Prof. Katayama's laboratory. He spent a year from 2008 to 2009 in Duke University (Prof. Chilkoti's lab) as visiting scholar. He promoted to associate professor in 2013 and professor in 2025 in Kyushu University. His research interest includes drug delivery and immunomodulatory materials. He founded start-up company of allergen immunotherapy in 2024.

Award

Young Scientist Award of the Society of Polymer Science, Japan (2010)

The number of patients with allergic diseases, including hay fever and food allergies, is increasing worldwide. Allergen immunotherapy is a treatment that can cure allergies, and in Japan, sublingual formulations have been approved for cedar pollen allergy and dust mite allergy. In contrast, injectable and sublingual formulations have been approved for a wide variety of aeroallergens in Europe and the United States, and Japan is lagging behind. Meanwhile, treatment of food allergies is not as common as treatment of aeroallergens due to the high risk of anaphylaxis, and is only performed at certain hospitals. In my research, I aim to develop a highly effective preparation for aeroallergens and food allergens that does not cause anaphylaxis.